Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients

Agnieszka Halon, Ewa Nowak-Markwitz, Adam Maciejczyk, Marek Pudelko, Tserenchunt Gansukh, B. Györffy, Piotr Donizy, Dawid Murawa, Rafal Matkowski, Marek Spaczynski, Hermann Lage, Pawel Surowiak

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). Materials and Methods: Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. Results: No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p=0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30% of cells) at PL had an increased overall survival time and progression-free time (p=0.00161 and p=0.03255, respectively) than the patients with lower ERβ espression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation.

Original languageEnglish
Pages (from-to)711-718
Number of pages8
JournalAnticancer Research
Volume31
Issue number2
Publication statusPublished - Feb 2011

Fingerprint

Estrogen Receptor beta
Ovarian Neoplasms
Drug Therapy
Survival
Cell Line
Laparotomy
Cisplatin
Immunohistochemistry
Kaplan-Meier Estimate
Cytoplasmic and Nuclear Receptors
Disease-Free Survival
Neoplasms

Keywords

  • Cisplatin
  • Estrogen receptor beta
  • Immunohistochemistry
  • Ovarian cancer
  • Prognostic factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. / Halon, Agnieszka; Nowak-Markwitz, Ewa; Maciejczyk, Adam; Pudelko, Marek; Gansukh, Tserenchunt; Györffy, B.; Donizy, Piotr; Murawa, Dawid; Matkowski, Rafal; Spaczynski, Marek; Lage, Hermann; Surowiak, Pawel.

In: Anticancer Research, Vol. 31, No. 2, 02.2011, p. 711-718.

Research output: Contribution to journalArticle

Halon, A, Nowak-Markwitz, E, Maciejczyk, A, Pudelko, M, Gansukh, T, Györffy, B, Donizy, P, Murawa, D, Matkowski, R, Spaczynski, M, Lage, H & Surowiak, P 2011, 'Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients', Anticancer Research, vol. 31, no. 2, pp. 711-718.
Halon, Agnieszka ; Nowak-Markwitz, Ewa ; Maciejczyk, Adam ; Pudelko, Marek ; Gansukh, Tserenchunt ; Györffy, B. ; Donizy, Piotr ; Murawa, Dawid ; Matkowski, Rafal ; Spaczynski, Marek ; Lage, Hermann ; Surowiak, Pawel. / Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. In: Anticancer Research. 2011 ; Vol. 31, No. 2. pp. 711-718.
@article{16916d98399941d7b1bd5debf0e6f5f7,
title = "Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients",
abstract = "Background: Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). Materials and Methods: Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. Results: No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p=0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30{\%} of cells) at PL had an increased overall survival time and progression-free time (p=0.00161 and p=0.03255, respectively) than the patients with lower ERβ espression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation.",
keywords = "Cisplatin, Estrogen receptor beta, Immunohistochemistry, Ovarian cancer, Prognostic factor",
author = "Agnieszka Halon and Ewa Nowak-Markwitz and Adam Maciejczyk and Marek Pudelko and Tserenchunt Gansukh and B. Gy{\"o}rffy and Piotr Donizy and Dawid Murawa and Rafal Matkowski and Marek Spaczynski and Hermann Lage and Pawel Surowiak",
year = "2011",
month = "2",
language = "English",
volume = "31",
pages = "711--718",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients

AU - Halon, Agnieszka

AU - Nowak-Markwitz, Ewa

AU - Maciejczyk, Adam

AU - Pudelko, Marek

AU - Gansukh, Tserenchunt

AU - Györffy, B.

AU - Donizy, Piotr

AU - Murawa, Dawid

AU - Matkowski, Rafal

AU - Spaczynski, Marek

AU - Lage, Hermann

AU - Surowiak, Pawel

PY - 2011/2

Y1 - 2011/2

N2 - Background: Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). Materials and Methods: Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. Results: No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p=0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30% of cells) at PL had an increased overall survival time and progression-free time (p=0.00161 and p=0.03255, respectively) than the patients with lower ERβ espression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation.

AB - Background: Estrogen receptor beta (ERβ) belongs to a large family of nuclear receptors. Recent studies have suggested that ERβ in contrast to ERα might act as a tumour suppressor in ovarian cancer (OVCA). Materials and Methods: Expression of ERβ was detected by immunocytochemistry in 11 OVCA cell lines and by immunohistochemistry in 43 (41 FIGO stage III) OVCA specimens prepared before chemotherapy and 30 specimens from the same group after chemotherapy. Cisplatin sensitivity in the 11 cell lines was also analysed. Results: No significant correlations between cisplatin-sensitivity and expression of ERβ was found in the cell lines. In the cases which responded well to chemotherapy (complete response) ERβ expression at preliminary laparotomy (PL) was significantly higher (p=0.0004) than in those with progressive disease. Kaplan-Meier analysis revealed that the patients with higher ERβ expression (>30% of cells) at PL had an increased overall survival time and progression-free time (p=0.00161 and p=0.03255, respectively) than the patients with lower ERβ espression. Significantly shorter overall survival time characterized the cases with lower immunoreactivity score of ERβ expression at secondary cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ expression in ovarian tumours may be a feature of malignant transformation.

KW - Cisplatin

KW - Estrogen receptor beta

KW - Immunohistochemistry

KW - Ovarian cancer

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=79953233108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953233108&partnerID=8YFLogxK

M3 - Article

C2 - 21378361

AN - SCOPUS:79953233108

VL - 31

SP - 711

EP - 718

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -